Destiny Pharma awarded significant new grant funding up to £1.6 million under new UK-China AMR programme
Two-year programme will research novel antimicrobial candidates from the Company's XF drug platform for use against dermal and ocularinfections
Brighton, United Kingdom - 25 January 2019 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the
development of novel antimicrobial drugs, that addresses the global problem of antimicrobial resistance (AMR), today announces it has
been awarded funding of up to £1.6 million from a collaboration established under the UK-China AMR grant fund set up by Innovate UK and
the Department of Health and Social Care with the Chinese Ministry of Science and Technology. The two-year project will examine the use
of the Company's novel XF drugs to prevent, control, and eradicate life threatening bacteria or "superbugs" without generating resistance.
The research work will be carried out by Destiny Pharma's team in collaboration with expert groups at Cardiff University's School of
Dentistry and College of Biomedical and Life Sciences, led by Professor David Williams, and a team at Tianjin Medical University, China.